NEUTRON CAPTURE SYNOVECTOMY FOR RHEUMATOID ARTHRITIS

中子捕获滑膜切除术治疗类风湿性关节炎

• 批准号: 2421655
• 负责人: RUTH E SHEFER
• 金额: $ 40.77万
• 依托单位: NEWTON SCIENTIFIC, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 1999-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2421655
• 关键词: boron; fingers; immunopathology therapy; inflammation; joints; knee; lithium; neutron radiation; orthopedics; particle accelerators; phantom model; radiation dosage; radiation therapy; radionuclides; rheumatoid arthritis; synovial membrane

The goal of this program is to determine the feasibility of synovectomy using the 10B(n,alpha)7 Li nuclear reaction with an external neutron beam for the treatment of rheumatoid arthritis (RA). This therapy has two potential advantages over surgical or radiation synovectomy with beta- emitters for RA: it is non-invasive and it does not require the administration of radioactive materials to the patient. Recent experiments have shown that very high boron concentrations can be achieved in active human synovium in vitro. However, the required neutron beam characteristics for therapy are presently unknown. In Phase I, Monte Carlo simulation techniques will be used to determine the required boron distribution and neutron beam parameters for successful therapy of the human synovial joints most commonly involved in RA. An optimized accelerator-based neutron beam design which minimizes radiation dose to non-target tissues in neutron capture synovectomy will then be developed. This work will lead to the construction of a neutron therapy beamline in Phase II and will provide the quantitative basis for future in vivo studies of synovial tissue ablation using the 10B(n,alpha) reaction. PROPOSED COMMERCIAL APPLICATION: Rheumatoid arthritis affects approximately 1% of the population of the United States. The proposed synovectomy procedure could be performed on an outpatient basis at about one-tenth the cost of a surgical synovectomy. If this technique is shown to be safe and effective, a large market for therapy beams will exist.

该计划的目标是确定滑膜切除术的可行性 使用外部中子束进行 10B(n,alpha)7 Li 核反应 用于治疗类风湿性关节炎（RA）。 这个疗法有两个 与手术或放射滑膜切除术相比，β-滑膜切除术的潜在优势 RA 发射器：它是非侵入性的，不需要 向患者施用放射性物质。 最近的 实验表明可以达到非常高的硼浓度 在体外活跃的人类滑膜中。 然而，所需的中子束 目前尚不清楚治疗的特点。 在第一阶段，将使用蒙特卡罗模拟技术来确定 成功所需的硼分布和中子束参数 治疗最常涉及 RA 的人类滑膜关节。 一个 优化的基于加速器的中子束设计，可最大限度地减少辐射 中子捕获滑膜切除术中非靶组织的剂量将是 发达。 这项工作将导致中子疗法的构建 第二阶段的光束线将为未来的光束线提供定量基础 使用 10B(n,alpha) 反应进行滑膜组织消融的体内研究。 拟议的商业应用：类风湿性关节炎影响 约占美国人口的1%。 拟议的 滑膜切除术可以在门诊进行，大约在 滑膜切除术费用的十分之一。 如果显示此技术 为了安全有效，治疗光束将存在一个巨大的市场。